Literature DB >> 29309629

Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy.

Konstantia Angelidou1, Peter W Hunt2, Alan L Landay3, Cara C Wilson4, Benigno Rodriguez5, Steven G Deeks2, Ronald J Bosch1, Michael M Lederman5.   

Abstract

Background: We examined changes in soluble inflammatory cytokines and T-cell activation after antiretroviral therapy (ART) initiation in an AIDS Clinical Trials Group (ACTG) nested case-control study.
Methods: Cases were 143 human immunodeficiency virus (HIV)-infected adults who developed a non-AIDS event; 315 controls remained event-free. Specimens were tested pre-ART, year 1 post-ART, and at the visit preceding the event. Conditional logistic regression evaluated the associations of biomarker changes with non-AIDS events.
Results: Inflammatory and most activation biomarkers declined from pre-ART to year 1 for cases and controls. Subsequently, inflammatory biomarkers remained mostly stable in controls but not cases. Cellular activation markers generally declined for both cases and controls between year 1 and the pre-event sampling. Controls with greater pre-ART RNA levels or lower CD4+ levels had higher biomarker levels while also experiencing greater biomarker declines in the first year of ART. Changes in biomarkers to year 1 showed no significant associations with non-AIDS events. Cases, however, had significantly greater increases in all plasma biomarkers (but not cellular activation) from year 1 to the visit preceding the event. Conclusions: Inflammation increases prior to non-AIDS events in treated HIV-infected adults. These biomarker changes may reflect subclinical disease processes or other alterations in the inflammatory environment that causally contribute to disease. Clinical Trials Registration: NCT00001137.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29309629      PMCID: PMC6009591          DOI: 10.1093/infdis/jix666

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

Review 1.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Peter W Hunt; Huyen L Cao; Conrad Muzoora; Isaac Ssewanyana; John Bennett; Nneka Emenyonu; Annet Kembabazi; Torsten B Neilands; David R Bangsberg; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

3.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.

Authors:  Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

4.  Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings.

Authors:  Rupak Shivakoti; Wei-Teng Yang; Sima Berendes; Noluthando Mwelase; Cecilia Kanyama; Sandy Pillay; Wadzanai Samaneka; Breno Santos; Selvamuthu Poongulali; Srikanth Tripathy; Cynthia Riviere; Javier R Lama; Sandra W Cardoso; Patcharaphan Sugandhavesa; Ashwin Balagopal; Nikhil Gupte; Richard D Semba; Thomas B Campbell; Robert C Bollinger; Amita Gupta
Journal:  J Infect Dis       Date:  2015-11-29       Impact factor: 5.226

5.  Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study.

Authors:  Ashwin Balagopal; David M Asmuth; Wei-Teng Yang; Thomas B Campbell; Nikhil Gupte; Laura Smeaton; Cecilia Kanyama; Beatriz Grinsztejn; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh G Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Xiao-Dong Li; Richard B Pollard; Richard D Semba; David L Thomas; Robert C Bollinger; Amita Gupta
Journal:  J Acquir Immune Defic Syndr       Date:  2015-10-01       Impact factor: 3.731

6.  Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study.

Authors:  Nikolas I Wada; Jay H Bream; Otoniel Martínez-Maza; Bernard Macatangay; Shannon R Galvin; Joseph B Margolick; Lisa P Jacobson
Journal:  Clin Infect Dis       Date:  2016-06-25       Impact factor: 9.079

7.  Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.

Authors:  Babafemi Taiwo; Roy M Matining; Lu Zheng; Michael M Lederman; Charles R Rinaldo; Peter S Kim; Baiba I Berzins; Daniel R Kuritzkes; Amy Jennings; Joseph J Eron; Cara C Wilson
Journal:  J Antimicrob Chemother       Date:  2013-04-18       Impact factor: 5.790

8.  Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.

Authors:  Elena Vendrame; Shehnaz K Hussain; Elizabeth Crabb Breen; Larry I Magpantay; Daniel P Widney; Lisa P Jacobson; Daina Variakojis; Emilee R Knowlton; Jay H Bream; Richard F Ambinder; Roger Detels; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

Review 9.  Immunologic basis of cardiovascular disease in HIV-infected adults.

Authors:  Priscilla Y Hsue; Steven G Deeks; Peter W Hunt
Journal:  J Infect Dis       Date:  2012-06       Impact factor: 5.226

Review 10.  Monocytes as regulators of inflammation and HIV-related comorbidities during cART.

Authors:  Joshua J Anzinger; Tiffany R Butterfield; Thomas A Angelovich; Suzanne M Crowe; Clovis S Palmer
Journal:  J Immunol Res       Date:  2014-06-12       Impact factor: 4.818

View more
  12 in total

1.  Undetectable = Untransmittable and Your Health: The Personal Benefits of Early and Continuous Therapy for HIV Infection.

Authors:  Mark J Siedner; Virginia Triant
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

2.  Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.

Authors:  Martin Hoenigl; Carlee B Moser; Nicholas Funderburg; Ronald Bosch; Amy Kantor; Yonglong Zhang; Jesper Eugen-Olsen; Malcolm Finkelman; Jochen Reiser; Alan Landay; Daniela Moisi; Michael M Lederman; Sara Gianella
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

3.  The Anti-inflammatory Effects of Cotrimoxazole Prophylaxis for People Living With Human Immunodeficiency Virus in Sub-Saharan Africa.

Authors:  Claire D Bourke; Andrew J Prendergast
Journal:  J Infect Dis       Date:  2020-07-06       Impact factor: 5.226

4.  Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus.

Authors:  Rebeca S De Pablo-Bernal; M Reyes Jimenez-Leon; Laura Tarancon-Diez; Alicia Gutierrez-Valencia; Ana Serna-Gallego; Maria Trujillo-Rodriguez; Ana I Alvarez-Rios; Yusnelkis Milanes-Guisado; Nuria Espinosa; Cristina Roca-Oporto; Pompeyo Viciana; Luis F Lopez-Cortes; Ezequiel Ruiz-Mateos
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  T-Cell Immune Dysregulation and Mortality in Women With Human Immunodeficiency Virus.

Authors:  Brandilyn A Peters; Jee-Young Moon; David B Hanna; Olaf Kutsch; Margaret Fischl; Caitlin A Moran; Adaora A Adimora; Stephen Gange; Nadia R Roan; Katherine G Michel; Michael Augenbraun; Anjali Sharma; Alan Landay; Seema Desai; Robert C Kaplan
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

Review 6.  Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities.

Authors:  Jehad Alzahrani; Tabinda Hussain; David Simar; Riya Palchaudhuri; Mohamed Abdel-Mohsen; Suzanne M Crowe; George W Mbogo; Clovis S Palmer
Journal:  EBioMedicine       Date:  2019-07-18       Impact factor: 8.143

Review 7.  HIV, Cancer, and the Microbiota: Common Pathways Influencing Different Diseases.

Authors:  Sabina Herrera; Javier Martínez-Sanz; Sergio Serrano-Villar
Journal:  Front Immunol       Date:  2019-06-27       Impact factor: 7.561

8.  Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study.

Authors:  Mark J Siedner; Mwebesa Bosco Bwana; Stephen Asiimwe; Gideon Amanyire; Nicholas Musinguzi; Jose Castillo-Mancilla; Russell P Tracy; Ingrid T Katz; David R Bangsberg; Peter W Hunt; Catherine Orrell; Jessica E Haberer
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

9.  Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States.

Authors:  Lauren F Collins; Anandi N Sheth; C Christina Mehta; Susanna Naggie; Elizabeth T Golub; Kathryn Anastos; Audrey L French; Seble Kassaye; Tonya N Taylor; Margaret A Fischl; Adaora A Adimora; Mirjam-Colette Kempf; Frank J Palella; Phyllis C Tien; Ighovwerha Ofotokun
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

10.  Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection.

Authors:  Samuel R Schnittman; Helen Byakwaga; Yap Boum; Jerome Kabakyenga; Lynn T Matthews; Tricia H Burdo; Yong Huang; Russell P Tracy; Jessica E Haberer; Annet Kembabazi; Angela Kaida; Daniela Moisi; Michael M Lederman; David R Bangsberg; Jeffrey N Martin; Peter W Hunt
Journal:  Open Forum Infect Dis       Date:  2021-05-17       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.